Last reviewed 2026-04-20 · How we verify

0,09% Bromfenac

Hospital de La Luz · FDA-approved active Small molecule Quality 13/100

0,09% Bromfenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) Small molecule drug developed by Hospital de La Luz. It is currently FDA-approved. Also known as: Zebesten.

Bromfenac 0.09% is a nonsteroidal anti-inflammatory drug (NSAID) ophthalmic solution developed by Hospital de La Luz for the treatment of postoperative ocular inflammation and pain. It is not approved by the FDA, which limits its use to specific regions or under special circumstances. The drug works by inhibiting cyclooxygenase enzymes, reducing prostaglandin synthesis and subsequent inflammation. Common side effects include eye irritation, blurred vision, and increased intraocular pressure. Due to its non-FDA approval status, it has limited commercial presence and no significant revenue data available.

At a glance

Generic name	0,09% Bromfenac
Also known as	Zebesten
Sponsor	Hospital de La Luz
Drug class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Target	Cyclooxygenase-2 (COX-2)
Modality	Small molecule
Therapeutic area	Ophthalmology
Phase	FDA-approved

Approved indications

No approved indications tracked.

Pipeline indications

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

0,09% Bromfenac CI brief — competitive landscape report
0,09% Bromfenac updates RSS · CI watch RSS
Hospital de La Luz portfolio CI

Frequently asked questions about 0,09% Bromfenac

What is 0,09% Bromfenac?

0,09% Bromfenac is a Nonsteroidal Anti-Inflammatory Drug (NSAID) drug developed by Hospital de La Luz.

Who makes 0,09% Bromfenac?

0,09% Bromfenac is developed and marketed by Hospital de La Luz (see full Hospital de La Luz pipeline at /company/hospital-de-la-luz).

Is 0,09% Bromfenac also known as anything else?

0,09% Bromfenac is also known as Zebesten.

What drug class is 0,09% Bromfenac in?

0,09% Bromfenac belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class. See all Nonsteroidal Anti-Inflammatory Drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is 0,09% Bromfenac in?

0,09% Bromfenac is FDA-approved (marketed).

What does 0,09% Bromfenac target?

0,09% Bromfenac targets Cyclooxygenase-2 (COX-2) and is a Nonsteroidal Anti-Inflammatory Drug (NSAID).

Drug class: All Nonsteroidal Anti-Inflammatory Drug (NSAID) drugs
Target: All drugs targeting Cyclooxygenase-2 (COX-2)
Manufacturer: Hospital de La Luz — full pipeline
Therapeutic area: All drugs in Ophthalmology
Also known as: Zebesten

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing